Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07358780 · ClinicalTrials.gov registry record

Remibrutinib in Real-world Clinical Practice - a US Sub-study

A clinical trial of Chronic Spontaneous Urticaria, sponsored by Novartis Pharmaceuticals.

Recruiting
Registry status
505
Enrollment target
1
Study location

NCT07358780: Recruiting study of Chronic Spontaneous Urticaria, sponsored by Novartis Pharmaceuticals.

NCT07358780 is a study of Chronic Spontaneous Urticaria that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 505 participants, below the 1,399-participant average among 18 other Chronic Spontaneous Urticaria trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07358780, a study of Chronic Spontaneous Urticaria, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.

RECRUITING
Registry status
505 participants
Enrollment target
1
Study location

Study Summary

Prospective, non-interventional study in patients with CSU where the treatment decision prior enrolment has been made to either escalate current sgH1-AHs treatment or escalate/switch current treatment to remibrutinib. The primary aim of this study is to gather real-world effectiveness and safety data for remibrutinib, a new treatment option, covering a broader, real-world clinical practice population.

Primary Outcome

Urticaria Activity Score over 7 days UAS7 is based on 2 daily questions scored 0-3 per day, ranging from 0 (complete control) to 42 (poor control)

Conditions Studied

Chronic Spontaneous Urticaria

Study Locations (1)

Missouri

  • Cleaver Dermatology - Kirksville

Trial Details

FieldValue
Enrollment Target 505 participants
Start Date 2026-02-02
Est. Completion 2029-09-30
Novartis Pharmaceuticals

1,375 total trials

What NCT07358780 shows while recruiting

NCT07358780 is an observational study that tracks outcomes without assigning an intervention. The registered 505 participants enrollment target is mid-sized for trials with a published cap, below the 1,399-participant average among 18 other Chronic Spontaneous Urticaria trials with a reported enrollment target (64% lower).

The record links to 1 condition, with Chronic Spontaneous Urticaria appearing as the primary indexed condition, and to 0 interventions.

NCT07358780 reports a single indexed study location in Missouri.

Frequently Asked Questions

What is clinical trial NCT07358780 about?

NCT07358780 is a clinical study titled "Remibrutinib in Real-world Clinical Practice - a US Sub-study". Prospective, non-interventional study in patients with CSU where the treatment decision prior enrolment has been made to either escalate current sgH1-AHs treatment or escalate/switch current treatment to remibrutinib. The primary aim of this study is to gather real-world effectiveness and safety dat...

What is the current status of trial NCT07358780?

This trial is currently recruiting. The enrollment target is 505 participants. The study started on 2026-02-02. Estimated completion is 2029-09-30.

What conditions does trial NCT07358780 study?

This clinical trial studies the following conditions: Chronic Spontaneous Urticaria.

Who is sponsoring clinical trial NCT07358780?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07358780 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Spontaneous Urticaria

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07358780's enrollment target sits among peer trials

505 8th of 18 higher than 11 of 18 other Chronic Spontaneous Urticaria trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Spontaneous Urticaria trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05069428 · 506 participants · Phase 4

    Delirium Reduction With Ramelteon

  • NCT05797168 · 506 participants · Phase 1

    Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

  • NCT05846282 · 504 participants · NA

    Students Rising Above: Offsetting the Health and Mental Health Costs of Resilience

  • NCT06072131 · 504 participants · Phase 3

    To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07358780

Source: ClinicalTrials.gov NCT07358780, the US trial registry maintained by the National Library of Medicine. NCT07358780 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.